IPOS Copy 9802413-6

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/40, 31/445, 31/55 — A1

(11) International Publication Number: **WO 97/13511**

(43) International Publication Date: 17 April 1997 (17.04.97)

(21) International Application Number: PCT/US96/16059

(22) International Filing Date: 7 October 1996 (07.10.96)

(30) Priority Data:
60/005,015 10 October 1995 (10.10.95) US

(71) Applicant *(for all designated States except US)*: ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US).


(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: BERG, David, T. [US/US]; 64 North 9th Avenue, Beech Grove, IN 46107 (US). GRINNELL, Brian, W. [US/US]; 3625 East 71st Street, Indianapolis, IN 46220 (US). RICHARDSON, Mark, A. [US/US]; 7811 North Thames Drive, Bloomington, IN 47408 (US).

(74) Agents: SALES, James, J. et al.; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 (US).


(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: METHODS OF INHIBITING PLASMINOGEN ACTIVATOR INHIBITOR 1



(I)



(a)



(b)

(57) Abstract

A method of inhibiting plasminogen activator inhibitor 1 comprising administering to a human in need thereof an effective amount of a compound having formula (I), wherein R^1 and R^3 are independently hydrogen, $-CH_3$, (a) or (b), wherein Ar is optionally s ubstituted phenyl; R^2 is selected from the group consisting of pyrrolidine, hexamethyleneimino, and piperidino; or a pharmaceutically acceptable salt or solvate thereof.